Cardio Diagnostics Holdings, Inc.
$1.97
0%
2026-04-21 05:57:00
cdio.ai
NCM: CDIO
Explore Cardio Diagnostics Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.95 M
Current Price
$1.97
52W High / Low
$17.4 / $0.97
Stock P/E
—
Book Value
$3.82
Dividend Yield
—
ROCE
-90.54%
ROE
-78.62%
Face Value
—
EPS
$-3.71
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
15
Beta
2.66
Debt / Equity
9.97
Current Ratio
9.79
Quick Ratio
9.79
Forward P/E
-7.32
Price / Sales
365.32
Enterprise Value
$1 M
EV / EBITDA
-0.16
EV / Revenue
67.51
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SpyGlass Pharma, Inc. | $24.52 | — | $833.66 M | — | -38.64% | -67.7% | $32.44 / $20.15 | $-44.85 |
| 2. | IGC Pharma, Inc. | $0.32 | — | $31.52 M | — | -114.73% | -83.34% | $0.5 / $0.24 | $0.09 |
| 3. | OnKure Therapeutics, Inc. | $4.99 | — | $68.37 M | — | -112.02% | -74.39% | $5.06 / $1.7 | $4.11 |
| 4. | Achieve Life Sciences, Inc. | $4.25 | — | $226.27 M | — | -167.79% | -2.58% | $6.03 / $1.95 | $0.4 |
| 5. | Caris Life Sciences, Inc. | $21.24 | — | $5.98 B | — | 4.52% | -45.37% | $42.5 / $16.28 | $2.04 |
| 6. | Pelthos Therapeutics Inc. | $22.95 | — | $77.23 M | — | -31.06% | -2.4% | $54.29 / $9 | $12.02 |
| 7. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0.01 M | 0 M | 0 M | — |
| Operating Profit | -1.46 M | -1.71 M | -1.68 M | -1.63 M | -1.52 M | — |
| Net Profit | -1.47 M | -1.71 M | -1.68 M | -1.64 M | -1.52 M | — |
| EPS in Rs | -0.5 | -0.58 | -0.57 | -0.55 | -0.51 | -1.73 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.01 M | 0.03 M | 0.02 M | 0 M |
| Operating Profit | -6.48 M | -8.37 M | -7.24 M | -4.55 M |
| Net Profit | -6.5 M | -8.38 M | -8.38 M | -4.66 M |
| EPS in Rs | -2.2 | -2.83 | -2.83 | -1.57 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.77 M | 10.62 M | 4.46 M | 6.25 M |
| Total Liabilities | 0.79 M | 1.06 M | 1.5 M | 1.95 M |
| Equity | 6.97 M | 9.56 M | 2.96 M | 4.3 M |
| Current Assets | 5.92 M | 8.79 M | 2.77 M | 5.89 M |
| Current Liabilities | 0.6 M | 0.63 M | 0.84 M | 1.95 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.73 M | -4.99 M | -5.67 M | -5.09 M |
| Investing CF | -0.42 M | -0.4 M | -0.79 M | -0.37 M |
| Financing CF | 3.43 M | 11.94 M | 3.63 M | 9.06 M |
| Free CF | -6.15 M | -5.4 M | -6.47 M | -5.17 M |
| Capex | -0.42 M | -0.4 M | -0.79 M | -0.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 104.45% | 1696.32% | — | — |
| Earnings Growth % | -0.08% | -79.72% | — | — |
| Profit Margin % | -24028.24% | -49087.81% | -490630% | — |
| Operating Margin % | -23977.86% | -42440.43% | -478784.32% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -23182.77% | -8966.9% | -488945.79% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-05-13 | 1:0.0333333 |